Bone Cancer - Pipeline Review, H1 2012

Description: Bone Cancer – Pipeline Review, H1 2012

Summary

Global Markets Direct's, 'Bone Cancer - Pipeline Review, H1 2012', provides an overview of the Bone Cancer therapeutic pipeline. This report provides information on the therapeutic development for Bone Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Cancer. 'Bone Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bone Cancer.
- A review of the Bone Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bone Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bone Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bone Cancer pipeline depth and focus of Bone Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Bone Cancer Therapeutic Products under Development, Key Players in Bone Cancer Therapeutics, Bone Cancer Pipeline Overview, Bone Cancer Pipeline, Bone Cancer Pipeline Assessment

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
**Bone Cancer Overview**

**Therapeutics Development**

**An Overview of Pipeline Products for Bone Cancer**

**Bone Cancer Therapeutics under Development by Companies**

**Bone Cancer Therapeutics under Investigation by Universities/Institutes**

**Late Stage Products**

**Comparative Analysis**

**Mid Clinical Stage Products**

**Comparative Analysis**

**Early Clinical Stage Products**

**Comparative Analysis**

**Discovery and Pre-Clinical Stage Products**

**Comparative Analysis**

**Bone Cancer Therapeutics – Products under Development by Companies**

**Bone Cancer Therapeutics – Products under Investigation by Universities/Institutes**

**Companies Involved in Bone Cancer Therapeutics Development**

- Genzyme Corporation
- Amgen Inc.
- Eli Lilly and Company
- Merck & Co., Inc.
- Infinity Pharmaceuticals, Inc.
- ZIOPHARM Oncology, Inc.
- ImClone Systems Incorporated
- Cephalon, Inc.
- Genta Incorporated
- Bayer AG
- Advaxis, Inc.
- Oncolytics Biotech Inc.
- Osteologix, Inc.
- Green Cross Corporation
- Algeta ASA
- Simcere Pharmaceutical Group
- Merrion Pharmaceuticals Plc
- Digna Biotech, S.L.
- Debiopharm Group
- Amura Holdings Ltd.
- Hawthorn Pharmaceuticals, Inc.
- Deciphera Pharmaceuticals, LLC
- Jennerex Biotherapeutics, Inc.
- Virobay Inc.
- PharmaMar, S.A.
- Targa Therapeutics Corp.
- Epeius Biotechnologies Corporation

**Bone Cancer – Therapeutics Assessment**

**Assessment by Monotherapy Products**

**Assessment by Combination Products**

**Assessment by Route of Administration**

**Assessment by Molecule Type**

**Drug Profiles**

- Xgeva - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- IMC-A12 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- G4544 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Ridaforolimus - Drug Profile
- Product Description
Product Description
Mechanism of Action
R&D Progress
Zymafos + Etoposide + Carboplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AM-3701 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Leuprolide + Doxorubicin Hydrochloride + Zoledronate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Endostar + Methotrexate + Cisplatin + Pirarubicin + Ifosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexrazoxane + Doxorubicin + Cisplatin + Methotrexate + Ifosfamide + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cytoxan + Doxorubicin + Vincristine + Irinotecan + Temozolomide + Neulasta + Mesnex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Etoposide + Carboplatin + Cyclophosphamide + Mesna + Melphalan + Tandem Peripheral Blood Stem Cell - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vincristine + Cyclophosphamide + Adriamycin + Etoposide + Cisplatin + Carboplatin + Melphalan + Ifosfamide + Granulocyte-Colony Stimulating Factor + Mesna - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VEGF/rGel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vincristine + Topotecan + Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vincristine + Doxorubicin + Cyclophosphamide + Dexrazoxane + ImmTher + Mesna + Neupogen + Neulasta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EF-2 Peptide + IL-2 + Autologous T-Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EF-2 Peptide + IL-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PXFK Peptide + IL-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PXFK Peptide + IL-2 + Autologous T cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E7 Peptide + IL-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E7 Peptide + IL-2 + Autologous T Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hydroxychloroquine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Carboplatin + Trastuzumab + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Rhenium-186 HEDP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MG1102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DCC-2909 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bone Cancer Therapeutics – Drug Profile Updates
Bone Cancer Therapeutics – Discontinued Products
Bone Cancer Therapeutics - Dormant Products
Bone Cancer – Product Development Milestones
Featured News & Press Releases
Apr 26, 2012: Amgen Receives Complete Response Letter From FDA For XGEVA sBLA For Prevention Of Bone Metastases
Apr 17, 2012: Daiichi Sankyo Launches RANMARK In Japan
Mar 31, 2012: Researchers State Combination Of Two Targeted Therapies Act Against Ewing's Sarcoma Tumors
Mar 29, 2012: NICE Recommends Use Of Amgen's Denosumab For Certain Groups Of Cancer Patients
Mar 20, 2012: Merck And ARIAD Provide Update On FDA Advisory Committee Vote On Ridaforolimus For Treatment Of Sarcomas
Mar 19, 2012: Medivir To File Application For Initiation Of Phase I Trials Of MIV-711
Feb 10, 2012: Analysis Of Updated ALSYMPCA Phase III Data Confirms Overall Survival Benefit Of Alpharadin In Castration-Resistant Prostate Cancer Patients With Bone Metastases
Feb 02, 2012: Algeta Announces Initiation Of Expanded Access Program For Alpharadin In US
Feb 01, 2012: Detailed Results From ALSYMPCA Phase III Study Highlight Positive Impact Of Alpharadin On Skeletal-related Events Associated With Bone Metastases From Castration-Resistant Prostate Cancer
Jan 27, 2012: Algeta Announces Results From ALSYMPCA Phase III Study With Alpharadin To Be Presented At 2012 Genitourinary Cancers Symposium
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Bone Cancer, H1 2012
Products under Development for Bone Cancer – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Genzyme Corporation, H1 2012
Amgen Inc., H1 2012
Eli Lilly and Company, H1 2012
Merck & Co., Inc., H1 2012
Infinity Pharmaceuticals, Inc., H1 2012
ZIOPHARM Oncology, Inc., H1 2012
ImClone Systems Incorporated, H1 2012
Cephalon, Inc., H1 2012
Genta Incorporated, H1 2012
Bayer AG, H1 2012
Advaxis, Inc., H1 2012
Oncolytics Biotech Inc., H1 2012
Osteologix, Inc., H1 2012
Green Cross Corporation, H1 2012
Algeta ASA, H1 2012
Simcere Pharmaceutical Group, H1 2012
Merrion Pharmaceuticals Plc, H1 2012
Digna Biotech, S.L., H1 2012
Debiopharm Group, H1 2012
Amura Holdings Ltd., H1 2012
Hawthorn Pharmaceuticals, Inc., H1 2012
Deciphera Pharmaceuticals, LLC, H1 2012
Jennerex Biotherapeutics, Inc., H1 2012
Virobay Inc., H1 2012
PharmaMar, S.A., H1 2012
Targa Therapeutics Corp., H1 2012
Epeius Biotechnologies Corporation, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Bone Cancer Therapeutics – Drug Profile Updates
Bone Cancer Therapeutics – Discontinued Products
Bone Cancer Therapeutics – Discontinued Products (Contd..1)
Bone Cancer Therapeutics – Dormant Products
Bone Cancer Therapeutics – Dormant Products (Contd..1)
Bone Cancer Therapeutics – Dormant Products (Contd..2)
Bone Cancer Therapeutics – Dormant Products (Contd..3)
Bone Cancer Therapeutics – Dormant Products (Contd..4)
Bone Cancer Therapeutics – Dormant Products (Contd..5)
Bone Cancer Therapeutics – Dormant Products (Contd..6)  
Bone Cancer Therapeutics – Dormant Products (Contd..7)  
Bone Cancer Therapeutics – Dormant Products (Contd..8)

List of Figures  
Number of Products under Development for Bone Cancer, H1 2012  
Products under Development for Bone Cancer – Comparative Analysis, H1 2012  
Products under Development by Companies, H1 2012  
Products under Investigation by Universities/Institutes, H1 2012  
Late Stage Products, H1 2012  
Mid Clinical Stage Products, H1 2012  
Early Clinical Stage Products, H1 2012  
Discovery and Pre-Clinical Stage Products, H1 2012  
Assessment by Monotherapy Products, H1 2012  
Assessment by Combination Products, H1 2012  
Assessment by Route of Administration, H1 2012  
Assessment by Stage and Route of Administration, H1 2012  
Assessment by Molecule Type, H1 2012  
Assessment by Stage and Molecule Type, H1 2012

Ordering:  
Order Online - http://www.researchandmarkets.com/reports/2141716/  
Order by Fax - using the form below  
Order by Post - print the order form below and send to  

Research and Markets,  
Guinness Centre,  
Taylors Lane,  
Dublin 8,  
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Bone Cancer - Pipeline Review, H1 2012
Web Address: http://www.researchandmarkets.com/reports/2141716/
Office Code: SCD2LPOB

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 1000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ____________________________ Last Name: ____________________________
Email Address: * ____________________________
Job Title: ____________________________
Organisation: ____________________________
Address: ____________________________
City: ____________________________
Postal / Zip Code: ____________________________
Country: ____________________________
Phone Number: ____________________________
Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World